Erythrocyte-bound apolipoprotein B in diabetes mellitus

Erythrocyte-bound apolipoprotein B in diabetes mellitus - EBADia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43369

Enrollment

250

Registered

2017-01-10

Start date

2016-12-19

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

artherosclerosis Diabetes

Interventions

Apolipoprotein B

Cardiovascular disease

Diabetes Mellitus

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Group with patients with T1DM or T2DM - Age of 18 years of older - Diabetes mellitus type 1 or type 2 Group with controles without T1DM or T2DM - Age of 18 years of older

Exclusion criteria

Exclusion criteria: Group with patients with T1DM or T2DM - Use of anti-inflammatory medication Group with controles without T1DM or T2DM - Diabetes mellitus type 1 or 2 - Use of anti-inflammatory medication - Chronic inflammatory disease (e.g. rheumatoid artheritis, inflammatory bowel disease, systemic lupus erythematosus)

Design outcomes

Primary

Measure	Time frame
The main endpoint of this study will be the value of erythrocyte-bound apolipoprotein B in patients with diabetes mellitus type 1 or 2.	—

Secondary

Measure	Time frame
Secondary endpoints will be the relation of erythrocyte-bound apolipoprotein B levels in patients with diabetes mellitus type 1 or 2 in association to clinical or subclinical atherosclerosis. Furthermore we will compare the level of and erythrocyte-bound apolipoprotein B in patients with diabetes mellitus against these levels in controls without diabetes mellitus. Finally, we want to study the levels of factors associated with complement activation in relation to ery- apo B values including DNA polymorphism.	—

Measure

Time frame

Secondary endpoints will be the relation of erythrocyte-bound apolipoprotein B levels in patients with diabetes mellitus type 1 or 2 in association to clinical or subclinical atherosclerosis. Furthermore we will compare the level of and erythrocyte-bound apolipoprotein B in patients with diabetes mellitus against these levels in controls without diabetes mellitus. Finally, we want to study the levels of factors associated with complement activation in relation to ery- apo B values including DNA polymorphism.

—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)